SLC5A2 and chronic kidney disease: Given the results, the fact that some types of intervention are predicted to be specifically beneficial in certain situations (e.g., SGLT2 inhibition indicating a benefit in most patients with a high risk of HF and CKD events, but not in subjects with a high risk of CAD events), and that this observation is in very good agreement with the observations in the intervention trials reported, further supports the validity of the approach.